Carregant...
A Phase II Study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia
Novel therapies for the treatment of acute myeloid leukemia are required to overcome disease resistance and to provide potentially less toxic therapies for older adults. Prior clinical trials involving patients with non-small cell lung cancer have demonstrated the safety and biologic activity of the...
Guardat en:
| Publicat a: | Leuk Res |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4860003/ https://ncbi.nlm.nih.gov/pubmed/24522247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.10.026 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|